Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
SCYNEXIS, Inc. (SCYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4,54, with a market capitalisation of $45,77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,53 to $9,20. This page covers its latest market performance, valuation, price trends and company information.
$45,77M | |
$4,51 | |
$1 200,00 | |
$3,53 | |
$4,39 | |
68,00 | |
136,72K | |
-- | |
$9,20 | |
$3,53 | |
-- | |
-- |
SCYNEXIS, Inc. (SCYX) is trading at $4,54 in pre-market trading as of 2026-09-16 11:45:00, up 3,30% ($0,15) from the previous close of $4,39
Pre-market trading shows how investors are pricing SCYX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, SCYNEXIS, Inc. (SCYX) moved from $5,30 to $4,54, representing a decline of 14,43% ($0,76).
The stock traded between $4,37 and $5,45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 48,14 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17,7%
SCYX is currently trading at $4,54, placing it 17,7% of the way from its 52-week low of $3,53 to its 52-week high of $9,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SCYNEXIS, Inc. (SCYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.